Related Experiment Video
Updated: Apr 26, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?
Antonio Di Biagio, Roberta Prinapori, Lucia Taramasso
1InfectiousDiseases Unit, IRCCS A.O.U. San Martino- IST, Genoa, Italy, Largo R. Benzi, 10, 16132 Genoa, Italy. antonio.dibiagio@hsanmartino.it.
Abstract:
Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Subviral Agents
Inhibitors of Viral Protein Synthesis
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

